Cefpodoxime
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Cefpodoxime | |||||||||||||||||||||
other names |
(6 R , 7 R ) -7 - {[(2 Z ) -2- (2-amino-1,3-thiazol-4-yl) -2-methoxyimino-acetyl] amino} -3- (methoxymethyl) - 8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid |
|||||||||||||||||||||
Molecular formula | C 15 H 17 N 5 O 6 S 2 | |||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class |
β-lactam antibiotics |
|||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 427.458 g · mol -1 | |||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Cefpodoxime is an antibiotic from the group of third generation cephalosporins and is administered orally (oral cephalosporin).
application
Cefpodoxime is used to treat infections
- the sinuses ,
- of the throat and tonsillitis ,
- the respiratory tract: acute bronchitis and pneumonia ,
- the urinary tract (uncomplicated), inflammation of the bladder and kidney pelvis ,
- the skin and soft tissues ,
- the urethra in uncomplicated gonorrhea .
It is also used as oral continuation therapy when intravenous cephalosporins are no longer necessary for sustained treatment. The antibiotic is also used in veterinary medicine.
It is recommended by the Paul Ehrlich Society as the drug of choice for the treatment of acute otitis media , acute sinusitis and the exacerbation of chronic bronchitis .
Spectrum of activity
Cefpodoxime is active against most gram-positive and gram-negative organisms.
Staphylococcus aureus ( methicillin- sensitive) is moderately to well sensitive . Other sensitive germs are Streptococcus pneumoniae , B-streptococci ( Streptococcus agalactiae ), Streptococcus pyogenes , Haemophilus influenzae , Moraxella catarrhalis , Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis and other enterobacteria .
Pseudomonas aeruginosa , enterococci , Bacteroides fragilis and Proteus vulgaris , for example, are naturally resistant . Some germs can be insensitive to cefpodoxime due to an acquired antibiotic resistance, e.g. Morganella morganii , Citrobacter spp. and Enterobacter spp.
application
Cefpodoxime is administered orally as a prodrug variant of cefpodoxime proxetil .
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
- ↑ H. Scholz, F. Vogel, Marianne Abele-Horn, D. Adam and others: Rational use of oral antibiotics in children and adolescents. Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V. In: Chemotherapy Journal. 11, 2002, pp. 59-70.
- ↑ F. Vogel, H. Scholz, B. Al-Nawas, W. Elies and others: Rational use of oral antibiotics in adults. Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V. In: Chemotherapy Journal. 11, 2002, pp. 47-58.
- ^ H. Scholz, KG Naber and the expert group of the Paul Ehrlich Society for Chemotherapy eV, Chemietherapie Journal 8, 1999, pp. 227–229 (PDF) ( Memento from September 20, 2009 in the Internet Archive ).
- ↑ a b Recommendations of an expert commission of the Paul Ehrlich Society for Chemotherapy e. V., Chemotherapy Journal 15, 2006, pp. 129-145 (PDF) ( Memento from September 20, 2009 in the Internet Archive ).
- ↑ Cefpodoxime Proxetil - a new cephalosporin for oral use. In: Journal for Infection Therapy. 1992, accessed February 16, 2016 .
- ↑ Product information Cefpodoxime Sandoz 100 mg film-coated tablets / 200 mg film-coated tablets / 40 mg / 5 ml powder for oral suspension. As of December 2007.